Annovis Bio, Inc.
(NYSE : ANVS)

( )
ANVS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.34%171.210.7%$969.79m
ABBVAbbVie, Inc. -0.61%138.071.9%$828.17m
PFEPfizer Inc. -1.22%49.250.9%$824.76m
LLYEli Lilly & Co. -1.47%301.311.1%$746.17m
MRKMerck & Co., Inc. 0.44%87.200.7%$738.11m
BMYBristol-Myers Squibb Co. 0.00%72.121.0%$649.82m
SIGASIGA Technologies, Inc. 19.67%23.300.0%$412.86m
AZNAstraZeneca Plc -0.39%66.031.0%$381.47m
ALNYAlnylam Pharmaceuticals, Inc. -2.44%218.588.1%$241.27m
GSKGSK Plc -0.07%40.570.3%$217.86m
HZNPHorizon Therapeutics Plc 3.88%69.605.4%$197.79m
SGENSeagen Inc. -0.03%175.815.7%$188.74m
NVSNovartis AG 0.40%85.570.2%$173.38m
RGENRepligen Corp. 1.22%246.276.7%$155.75m
NVONovo Nordisk A/S -1.20%103.220.1%$152.93m

Company Profile

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.